

Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?

A case report and literature review

Lei Wang, MD, PhD, Xiaojing Yan, MD, PhD, Juan He, MD, PhD*

Abstract

Rationale: Most acute promyelocytic leukemia (APL) patients respond to all-trans-retinoic acid (ATRA)and have a good prognosis. However, variants APL who carry PLZF/RARa, STAT5B/RARa, and STAT3/RARa are insensitive to ATRA and have poor prognoses. The standard treatment for variants APL is still unclear due to the small sample size.

Patient concerns: Here we reported a Chinese male who was admitted to our hospital with the complaint of rib pain, dyspnea, and fever (37.5°C). Blood tests showed leukopenia (1.83×10^{9} /L), anemia (hemoglobin 73 g/L), and thrombocytopenia (54×10^{9} /L). Prothrombin time and activated partial thromboplastin time were normal.

Diagnoses: The patient was diagnosed as STAT5b-RARa-positive APL based on the clinical and laboratory findings.

Interventions: ATRA was used immediately for induction treatment, then he was treated with ATRA + arsenic trioxide and got the severe cardiac insufficiency. Subsequently, consolidation chemotherapy was added with ATRA + Huangdai tablets + idarubicin and decitabine, cytarabine, aclamycin (DCAG).

Outcomes: The patient relapsed soon after his first molecular complete remission (CRm), fortunately, he got a second CRm with DCAG. He has survived for more than 9 months and remains CRm, now he is looking for a suitable donor to prepare for hematopoietic stem cell transplantation (HSCT).

Lessons: APL patients with STAT5B-RARa is not only resistant to ATRA, but also to conventional combination chemotherapy such as daunorubicin and cytarabine/idarubicin and cytarabine or other regimens. Relapse and extramedullary infiltration is common, HSCT is a effective treatment, and the best time for HSCT is after the first CR. It should be noted that this patient got CRm with DCAG after relapse, so the role of decitabine in APL with STAT5B-RARa needs to be considered.

Abbreviations: APL = acute promyelocytic leukemia, ATO = arsenic trioxide, ATRA = all-trans retinoic acid, CR = complete remission, CRm = molecular complete remission, DA = daunorubicin and cytarabine, DCAG = decitabine, cytarabine, aclamycin, G-CSF, DIC = disseminated intravascular coagulation, HSCT = hematopoietic stem cell transplantation, IA = idarubicin and cytarabine.

Keywords: acute promyelocytic leukemia, all-trans retinoic acid, PML-RARA, prognosis, STAT5B/RARa

1. Introduction

More than 98% of acute promyelocytic leukemia (APL) patients have classic t(15,17)(q22;q12-23) and promyelocytic leukemia-retinoic acid receptorA (PML-RARA) fusion genes; they respond to all-trans retinoic acid (ATRA) and have a good prognosis.

However, RARa fuses with other partner genes in patients with variants APL (1%–2%), and some new fusion proteins have been formed, such as PLZF/RARa, NPM/RARa, NuMA/RARa, STAT5B/RARa, FIP1L1/RARa, PRKAR1A/RARa, and BCOR/RARa. APL patients with PLZF/RARa, STAT5B/RARa, and

Editor: Maya Saranathan.

Received: 15 January 2020 / Received in final form: 18 September 2020 / Accepted: 25 September 2020

http://dx.doi.org/10.1097/MD.00000000022923

The patient had provided informed consent for publication of the case.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

This work was supported in part by grants from the National Natural Science Foundation of China (No. 81170519) and the Fok Yingdong Education Foundation for Young Teachers in Colleges and Universities (No. 141031).

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China.

^{*} Correspondence: Juan He, Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China (e-mail: hejuan_2006@126.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Wang L, Yan X, He J. Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine? a case report and literature review. Medicine 2020;99:43(e22923).




Figure 1. Laboratory examination result of this patient. (A) Abnormal promyelocyte in bone marrow ($100 \times oil$ objective), (B) Peroxidase staining of bone marrow ($100 \times oil$ objective), (C) Flow cytometric analysis of BM cells showing a population of abnormal cell (P3: 61.6%). (D) STAT5B-RARa fusion transcript detected by RT-PCR analysis in this patient. (E) Karyotype of this patient:43,-46,XY,+2,-5,+8,14p+,-16,17q-,17q+,+18,-19, 20, 21, +mar1, +mar2 [CP5]/46,XY[15]. BM = bone marrow, RT-PCR = reverse transcription–polymerase chain reaction.

STAT3/RARa are insensitive to ATRA.^[1] Patients with variants APL often have poor prognoses. The STAT5B/RARa fusion gene is rare in APL and was first reported in 1996.^[2] To date, 16 cases have been reported. The standard treatment for variants APL is still unclear due to the small sample size. Here, we report a 62-year-old man diagnosed as APL with STAT5B/RARa and summarize the clinical features and effective treatment, hoping to improve the prognosis of these patients.

2. Case report

A 62-year-old man was admitted to the hospital with the complaint of rib pain, dyspnea, and fever (37.5°C). Blood tests showed the following results: white blood cell count $1.83 \times$ 10⁹/L, hemoglobin 73 g/L, platelet count 54×10^{9} /L, prothrombin time 13.6 seconds, activated partial thromboplastin time 38.8 seconds, fibrinogen 5.8 g/L, D-dimer 2.4 µg/mL, fibrinogen degradation products 8.15 µg/mL. Abnormal promyelocyte in bone marrow aspiration showed 80.4% of blast, and flow cytometry indicated mainly positivity for CD33 and myeloperoxidase, partially positivity for CD117, CD9, CD11b, CD13, CD15 and CD64; negativity for CD7, CD19, CD10, cCD3, cCD79a, CD16, CD123, HLA-DR, CD14, CD56, CD3, CD4, CD8, CD2, and CD11c. Cytogenetics showed 43,-46,XY, +2,-5,+8,14p+,-16,17q-,17q+,+18,-19,-20,-21,+mar1, +mar2[CP5]/46,XY[15] (Fig. 1A). STAT5B/RARa fusion transcript was detected by reverse transcription-polymerase chain reaction. Given the clinical and laboratory findings, he was diagnosed as APL with STAT5B/RARa and treated with ATRA monotherapy for the first course, and no granulocyte differentiation was observed. However, his fibrinogen degradation product and D-dimer levels improved and he got a complete remission (CR) after the first course. Then he was treated with ATRA + arsenic trioxide (ATO) during the second course. But unfortunately, he was transferred to the intensive care unit because of severe cardiac insufficiency (BNPmax 1361 pg/mL) on the 14th day of the second course. However, STAT5B/RARa was still positive (17.96%) after the second course. He received 3 courses of ATRA + Huangdai tablets (ATO oral forms) + idarubicin in the following consolidation treatment and got molecular complete remission (CRm) after the fourth course, but STAT5B/RARa turned to be positive (0.6%) again after the fifth course. Fortunately, he got a second CRm with DCAG (decitabine [15 mg/m², D1-5], cytarabine [10 mg/m², q12, D3-9], aclamycin [8 mg/m², D3-6], G-CSF [200 ug/m², D0-1, till white blood cell count $>20 \times 10^{9}$ /L]). This patient is now looking for a suitable donor to prepare for hematopoietic stem cell transplantation (HSCT).

3. Discussion

STAT5B is located on chromosome (Chr)17q21.1-21.2 and mainly distributed in the cytoplasm and nucleus. It regulates cell proliferation and induces leukemia through JAK-STAT signaling pathways. STAT5B plays a role in preventing further differentiation of hematopoietic cells together with the corepressor complex of deacetylase, this complex cannot be released by ATRA. This may explain the resistance of APL with STAT5B/RARa to ATRA.

The current case showed a complex karyotype and an unsatisfactory treatment process. He was responsive to ATRA

	ase	vear of								ATRA	ATRA-induced					
Age Gamoer Factories Factories Factories Technics Curso Outcome Technics Curso Outcome Technics Techni	Case						WBC				granulocytic				Effective	
			Age	Gender			(×109)		DIC		differentiation	Therapy	Course		treatment	00 (mo)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Arnould C, 2015 ^[3]	67	Μ	45,X,-Y,add(17)(q?)[40]	M1/M3v	6.7	NA	+	NA		ATRA	-	NR	None	NA
Researche M Carlo IIII Continue 1 Chi Fini dapase M pend ri Bin p		S. Strehl, 2013 ^[4]	57	Σ	46,XY,t(10;11)(q22;q25),i(17)	M3	23.8	NA	+	NA		ATRA		NR	DA	18 mo
Kestedee M 42 M 46X-V+11g/46X/111 MB 35 125 + YES ND ATM AS ATM AS 2008 ¹⁷ 41 M 45X-V+11g/46X/111 MB 315 125 + YES ND ATM Scord 63 Scord 63 Scord 63 Scord 63 Scord 63 Scord 63 NHM+ 21 21 NHM+ 21 NHM+ 21 21 NHM+ 21 21 NHM+ 21 21 NHM+ 21 2					(q10)							DA		CR, First relapse: BM	gemtuzumab	
Kessense 2 M 45X,Y+119/46XX[11] MS 15 Y = Y Second GA, above Second GA, above Second GA, above Second GA, above None data bear None data bear												Gemtuzumab	. 	at 9 mo	ozogamicin	
Kuskele M, 20 A 42 M 45X.V;+1(9)46X/I(1) MS 125 + YES NO AMT MoST Doub at 16 no. Doub at 16 no. Doub at 16 no. NHA+ I 200 NHA+ I 17 WHB PM 10 NHA+ 1 10 NHA+ 1 11 NHA+ 1 11 NHA+ N NHA+ <												ozogamicin		Second CR.		
Kusakala A Mit AS Max Mit Z Mit <thz< th=""> Mit Mit</thz<>												allo-SCT		Dead at 18 mo		
2008 ¹⁰ 1 4 4/1 M + up16 1 C VP16 VP16 Rengg E 41 47X(se0)(r/p)de(17) N3 77.8 95 + M1 716 V716 V716 200 ¹⁰¹ 201, + interflocal 0 + interflocal 1 8 - cond 717.4 1 1 200 ¹⁰¹ 25 M +<	3	Kusakabe M,	42	Σ	46,X,-Y,+11[9]/46,XY,[11]	M3	3.6	125	+	YES		ATRA	-	NR	DA + Mit +	21 mo
Mentale field 41 M. 47.X(seb)(n(7) and(17), (am) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2		2008 ^[5]										DA + MIT + vp16	-	CR	VP16	
Wanger 41 M 27X(ABD)(07) and(17) M3 778 55 H M ATRA + IA 1 C ATRA + IA 1 C 2009 ¹¹ annuar(17)												HD-Ara-C	5	CR		
200 ⁶¹ (12), -tirent [3],48,XY, ATR, + IA 2 Fit states and indication intermedial inclusion intermedial is sound of stores information intermedial. 2 Fit states and inclusion intermedial inclusion intermedial. 1 Control expanse minimadial. Joenovie, UV. 29 F 46,XX(5);17(q26)q2;1) M3 5.6 MA + NA NA + NA + NA + NA NA + NA NA + NA + NA + NA + NA NA NA + NA NA NA NA + NA NA NA NA NA NA NA NA NA		lwanaga E,	41	Σ	47,XY,(del9),(q?),add(17)	M3	77.8	95	+	NA		ATRA + IA	. 	CR	ATRA + IA	17 mo
Identificial Identification Identific		2009 ^[6]			(q12), +mar1 [3].48,XY,							ATRA + IA	2	First relapse: meningeal		
Joanove, JV, 2011 ¹⁷ 29 F 46.XX(a:17)(q26:q21) M3 5.6 Ma + Mole bear instation Sound reference BM, ano B Sound reference BM, and reference BM, ano B Sound reference BM, and reference BM, ano B Ma					idem,mar1[17]							HD-Ara-C + intrathecal	, -	second CR for 6 mo		
												chemotherapy +		Second relapse: BM,		
Joranovc JV, 2011 29 F 46.XXIG:17)(Q56:q21) M3 56 NA + M NO ATRA + IA 1 CR (no Chn) ATRA + IA 1 2011 2011 32; M 46.XX M3 33 282 + M0 NO ATRA + ATO + MT 1 R (no Chn) ATRA + IA 12 Qao G, 2011 32; M 46.XY M3 33 282 + N0 NO ATRA + ATO + MT 1 R (no Chn) ATRA + IA 12 M3 M3 M4												whole brain irradiation		Died		
2011 ⁷¹ EA 1 NB alu-BMT alu-BMT alu-BMT alu-BMT alu-BMT alu-BMT cmplications: alu-BMT alu-BMT alu-BMT alu-BMT cmplications: alu-BMT alu-BMT alu-BMT alu-BMT alu-BMT alu-BMT alu-BMT cmplications: alu-BMT	5	Jovanovic JV,	29	ш	46,XX,t(3;17)(q26;q21)	M3	5.6	NA	+	NA		ATRA + IA	. 	CR (no CRm)	ATRA + IA	15 mo
Date C, 2011 32: M 45.XY M3 38 282 + N0 ATRA + K10 + M1 1 NR ELdG alloHSCT 9 Chen H, 2012 26 M 45.XY M3 38 282 + N0 ATRA + K10 + M1 1 NR ELdG alloHSCT 9 Chen H, 2012 26 M 45.XY M3 6.6 9.4 + NA NA 1 0.7		2011 ^[7]										FLA	, -	NR	allo-BMT	
												allo-BMT		CR; Dead of BMT-related		
Qiao C, 2011 32, M 46,XY M3 38 282 + N0 NTRA + AT0 + MT 1 NR FL46 10, CR Chen H, 2012 26 M 46,XY M3 56 94 + NA ATRA 1 CR Mone NV Chen H, 2012 26 M + N NA ATRA 1 NR None NV Strein S, 2013 17 M 46,XY, Ader(13), 2der(13), 2der(13), 2der(13), 2der(14) M3 2.8 NA + NO NA ATRA 1 NR NOne NV 2013 17 M 46,XY, 2der(13), 2der(13), 2der(17q) M3 2.8 NA + NO NA ATRA 1 NR ND ND <td></td> <td>complications;</td> <td></td> <td></td>														complications;		
Wang Yi, 22 M 46X/rink(9)(34(13)) M3 6.6 94 + NA NBA 1 0.8 None NV Strehl S, 17 M 46X/riadr(13)/2def(17q) M3 6.6 94 + NA NBA 1 NB None NV Strehl S, 17 M 46X/riadr(13)/2def(17q) M3 2.8 NA + NO NB NBA ND		Oian C. 2011 ^[8]	32.		46.XY	M3	3.8	282	+	ON		ATRA + ATO + MIT	-	NB	FI AG allo-HSCT	96 d after allo-
Chen H, 2012 26 M 46,XY M3 5.6 9.4 + MA 1 CR More W Strehl S, 1 7 M 46,XY M3 5.6 9.4 + MA 1 NR N Strehl S, 1 7 M 46,XY M3 2.8 NA + NO N N NR NR N N Strehl S, 1 M 46,XY M3 2.8 NA + NO N N N N N N Strehl S, 1 M 46,XY MA N N N N N N N N N N N Strehl S, 10 T MA MA N			Î									FLAG	-	CR		HSCT: ongoind
Chen H, 2012 26 M 46,YY M3 6.65 94 + NA NA T N None Streht S, 2013 17 M 46,YY?der(13);2def(17q) M3 2.8 NA + NO MRA 1 NR None Streht S, 2013 17 M 46,YY?der(13);2def(17q) M3 2.8 NA + NO NA 1 NR None 2013 101 6 NA + NO NA 1 NR None 2013 101 17 M 46,Y??der(13);2def(17q) M3 2.8 NA + NP16 1 N 2013 101 17 M 46,Y??der(13);2def(17q) M3 2.8 NA + NP16 1 1 NP16 2013 17 M 46,Y??der(13);2def(17q) M3 2.8 NA + NP16 1 1 1 NP16 2013 10 10 1 1 1 <												FLAG	, -	CR		
Chen H, 2012 B 46,YY M3 6.6 9.4 H NA ATRA 1 NR None Strein S., 2013 17 M 46,XY,704r(13),764r[17a] M3 2.8 MA + NO NA ATRA 1 CR NR ATRA 1 NR ATRA N ATRA 1 NR ATRA N NP16 ATRA N NP16 ATRA N NP16 ATRA N NP16												allo-HSCT		CR		
Streht S, 2013 17 M 46.XY,2der(13),2der[17q] M3 2.8 NA + NO MRA ATD 1 NR Streht S, 2013 17 M 46.XY,2der(13),2der[17q] M3 2.8 NA + NO 1 C C Rent S, 2015 17 M 46.XY,2der(13),2der[17q] M3 2.8 NA + NO 1 C Rent A M MA MA 1 2.4 M0 M1A, IA, IA, IA, IA, IA, IA, IA, IA, IA, I	~	Chen H, 2012 ^[9]	26	Σ	46,XY	M3	6.6	94	+	NA		ATRA	, -	NR	None	NA
Stehl S, 2013 17 M 46.XY.7der(13).7der(17q) M3 2.8 NA + N0 MA ATRA 1 MR ATRA, IA, ATRA, IA T If References tests VP16 2013 In1 M 46.XY.7der(13).7der(17q) M3 2.8 NA + N0 NA ATRA, IA 1 CR VP16 2013 In1 RTRA, IA 1 RTRA, IA 1 R12, 4100 VP16 ATRA, IA ATRA, IA 1 R1A, ATRA 1 R12, 4100 VP16 ATRA, IA ATRA, IA 1 R1A, ATRA 1 R200 R1 ATRA, IA 1 RA ATRA 1 Record relapse: BM at ATRA, IA 1 RA ATRA 1 RC ATRA, IA ATRA, IA 1 RA ATRA 1 RC ATRA ATRA 1 RA ATRA 1 ATRA IA ATRA ATRA 1 RA												IA	, -	NR		
Strein S, 2013 17 M 46,XY,?der[17] M3 2.8 NA + N0 MA ATRA 1 CR ATRA, IA, 1 2013 101 2013 101 1 + VP16 1 First relapse: tests VP16 2013 101 ATRA + IA 1 1 at 24 mo VP16 ATRA 1 ATRA 1 8cond CR VP16 VP16 <td></td> <td>-</td> <td>ATRA + ATO</td> <td>, -</td> <td>NR</td> <td></td> <td></td>											-	ATRA + ATO	, -	NR		
2013 ^[10] IA + VP16 1 First relapse: testis VP16 ATRA + IA 1 at 24 mo VP16 + HD-AraC + 1 NR ATRA + IA 1 Second CR ATRA 1 Second CR ATRA + IA 1 NR + ATRA 1 Second CR NR ATRA + IA 1 Second CR NR ATRA 1 Second CR ATRA + IA 1 NR + ATRA 1 ATRA 1 Atra ATRA + IA 1 NR + ATRA 1 Atra	60	Strehl S,	17	Σ	46,XY,?der(13),?der[17q]	M3	2.8	NA	+	NO		ATRA	-	CR	ATRA, IA,	53 mo
Wang W, 2015 ^[11] 22 M 46.XV, inv. (9)(013q13)c13)/ [10pt] 33 125 + YES NO ATRA 1 at 24 mo Wang W, 2015 ^[11] 22 M 46.XV, inv. (9)(013q13)c13)/ [10pt] M3 23 125 + YES NO ATRA 1 Dead at 53 mo Wang Y, 2015 ^[11] 22 M 46.XV, inv. (9)(013q13)c13)/ [10pt] M3 2.3 125 + YES NO ATRA 1 NR Mang Y, 2015 ^[11] 22 M 46.XV, inv. (9)(013q13)c 1 1 NR Mang Y, 2015 ^[11] 22 M 46.XV, inv. (9)(013q13)c 1 1 NR Mang Y, 2015 ^[11] 23 125 + YES NO ATRA 1 NR Mang Y, 10pt 1 1 1 NR None		2013 [10]										IA + VP16	.	First relapse: testis	VP16	
Wang Yv, 2015 ^[11] 22 M 46, Xinv.(9)(013q13)c[18]/ (204J) (22] M3 470 1 NR Second CR ATO 1 Second CR Second relapse: BM at ATO 1 Second CR ATO M4 + ATRA 1 Second CR Second relapse: BM at ATO M4 + ATRA 1 Second CR ATO M4 - ATRA 1 Second CR ATO M4 - ATRA 1 Second CR ATO M4 - ATRA 1 NR M4 - ATRA 1 Atta Atta Atta Atta Atta Atta Atta Atta												ATRA + IA	-	at 24 mo		
Mark FTIPA 1 Second CR MA + ATRA 1 Second CR MA + ATRA 1 Second CR MA + ATRA 1 Second relapse: BM at ATO 1 ATO 1 ATO 1 A0 mo ATO 1 Nm + ATRA 1 Nm ATO 1 Nm + ATRA 1 Nm ATO 1 Nm dunoxome 1 Nm 2015 ^[11] 22 M 46.XV,inv.(9)(p13q13)c18/ M3 2.3 125 + YES NO ATRA 1 NR 2015 ^[11] Cp44/ [22] M1 1 NR None ATO ATO 1 Nn 2015 ^[11] Cp44/ [22] M1 1 NR None												VP16 + HD-AraC +	-	NR		
Wang Yv, 2015 ^[11] 22 M 4.0.Vinv.(9)(p13q13)c[18]/ (p24) MA + ATRA 1 Second relapse: BM at ATO MA + ATRA 1 Second relapse: BM at ATO Wang Yv, 2015 ^[11] 22 M 46.XV, inv.(9)(p13q13)c[18]/ (144-5, XV, inv.(9)(p13q13)c 3 3.3 125 + YES NO ATMA 1 NR None Vang Yv, 2015 ^[11] 22 M 46.XV, inv.(9)(p13q13)c 3 2.3 125 + YES NO ATMA 1 NR None Vinv (2) A14-45, XV, inv.(9)(p13q13)c 3 2.3 125 + YES NO ATMA 1 NR None Pedd turber Refused further 1 NR None Non												ATRA	, -	Second CR		
Wang Yv, 2015 ^[11] 22 M 46.XV,inv.(9)(p13q13)c[18]/ (p24) M3 2.3 125 + YES NO ATM 1 Man Wang Yv, 2015 ^[11] 22 M 46.XV,inv.(9)(p13q13)c[18]/ (a14-5,XV,inv.(9)(p13q13)c 3.3 125 + YES NO ATM 1 NR None PLA A14-45,XV,inv.(9)(p13q13)c 2.3 125 + YES NO ATM 1 NR None Perform FLA Ammoranine 1 NR None ATM 1 NR Perform Refused further 2016, Hr 1 NR None												MA + ATRA	-	Second relapse: BM at		
Wang YY, 2015 ^[11] 22 M 46,XY,inv.(9)(p13q13)c[18]/ (p24) 32.3 125 + YES NO ATRA 1 NR Wang YY, 2015 ^[11] 22 M 46,XY,inv.(9)(p13q13)c[18]/ (p14) 32.3 125 + YES NO ATRA 1 NR None PLA At-45,XY,inv.(9)(p13q13)c 2.3 125 + YES NO ATRA 1 NR None PLA ATRA 1 NR 1 NR None Place ATO + IA 1 NR Dead None												ATO	. 	40 mo		
Wang YY, 22 M 46,XY,inv.(9)(p13q13)c[18]/ (p24) 3 2.3 125 + YES NO ATRA 1 NR None 2015 ^[11] 244-5,XY,inv.(9)(p13q13)c 2.3 125 + YES NO ATRA 1 NR None 2015 ^[11] 2,015 H ATRA 1 NR None 2015 ^[11] 10,013 2.3 125 + YES NO ATRA 1 NR 2015 ^[11] 10,013 2.3 125 + YES NO ATRA 1 NR 2015 ^[11] 10,014 1 NR None ATV NO ATV ATV NO												fludarabine + Ara-c +	. 	NR		
FLA + auto-HSCT 1 RLA FLA RLA FLA Vang YY, 22 M 46,XY,inv.(9)(p13q13)c[18]/ M3 2.3 125 + YES NO ATRA 1 NR None 2015 ^[11] 44-45,XY,inv.(9)(p13q13)c 2.3 125 + YES NO ATRA 1 NR [cp4]/<[22]												daunoxome	. 	Dead at 53 mo		
FLA FLA Wang YY, 22 M 46,XY,inv.(9)(p13q13)c[18]/ M3 2.3 125 + YES NO ATRA 1 NR<												FLA + auto-HSCT	, -			
Wang YY, 22 M 46,XY,inv.(9)(p13q13)c[18]/ M3 2.3 125 + YES NO ATRA 1 NR None 2015 ^[11] 44-45,XY,inv.(9)(p13q13)c 2.3 125 + YES NO ATRA 1 NR None 2015 ^[11] 44-45,XY,inv.(9)(p13q13)c 2.3 125 + YES NO ATO + IA 1 NR [cp4]Y [c22] Equal Y Ecual further Dead												FLA				
Wang YY, 22 M 46,XY,imv,9)(p13q13)c M3 2.3 125 + YES NO ATRA 1 NR None 2015 ^[11] 44-45,XY,imv,(9)(p13q13)c 2.3 125 + YES NO ATO + IA 1 NR [cp4]/ [22] [cp4]/ [22]												FLA + amsacrine				
44-45,XY,inv.(9)(p13q13)c AIO + IA T C = C = C = C = C = C = C = C = C = C	0	Wang YY,	22	Σ	46,XY,inv.(9)(p13q13)c[18]/	M3	2.3	125	+	YES		ATRA	, –	NR	None	9 mo
Refused further		2015"			44-45,XY,inv.(9)(p13q13)c							ATO + IA	, -	NR		
					[cp4]/ [22]							Refused further		Dead		

3

Table 1

(continued)

ase	year of publication and Case reference number Age Gender	Age	Gende	sr Karyotype	FAB	WBC (×109)	РLТ (×109)	DIC	ATRA improve FDP, D-D	ATRA-induced granulocytic differentiation	Therapy	Course	Outcome	Effective treatment	(om) S0
10	Liu Lirong, 2016 ⁽¹²⁾	49	Σ	46,XY[20]	^M 3	19.7	24	+	NA	₹ <u>N</u>	ATRA + ATO + idarubicin IA HHT + MD-Ara-C; idarubicin + MD-Ara-C FLAG HHT + MD-Ara-C; ATO	-4	CRm First relapse: BM NR NR NR	ATRA + ATO + idarubicin IA HHT + MD-Ara-C;	More than 15 mo
÷	Zhang C, 2018 ^[13]	28	щ	46,XX[20]	M3	1.95	196	+	NA	NA	ATRA ATRA + idarubicin ATO/ATRA + DA		AN N 200	None	2 mo
12	Kluk MJ, 2015 ^[14]	47	Σ	45, X, -Y/46,XY	M3	2.1	135	+	NA	NA	ha + aira ATRA DA usct		Dead NR NP	HSCT	9 mo
13	Wang A, 2018 ^[15]	47.	Σ	46, XY, t(5;7)(q22;q31)/ 46,XY,der(11)/46,XY	M3	17.18	78	+	ON	NA	ATRA/mitoxantrone + ATO, IA;	0	RN RN GR	Decitabine + AA/IA	12 mo; ongoing
14	Ciangola G, 2019 ⁽¹¹⁸⁾	47	Z	46,XY,der(5)t(5,8)	M3	1.6	229	ı	N	ON	ATRA ATRA DA FLG-IA + ATRA Allo-HSCT		NR NR CR CR, dead of CR, dead of feilure feilure	RLAG-IA + ATRA	NA
15	Peterson JF, 2019 ^[17]	27	Σ	46, XY	M3	52	24	+	NA	YES	ATRA + Hydroxyurea		Dead	None	3.5 d
16		32	Σ	45,X,Y,der(17)inv(17) (p11.2q21)del(17) (n21)/46,XY	M3	6.8	126	+	NA	NA	ia Flag-ida Alio-HSCT	- 0	NR RN RO	Allo-HSCT	12 mo after HSCT; Ongoing
17	Current case	62	Σ	43,-40, 20, 42,-5,+8,14p +,-16,17q,17q,17q+, +18,-19,-20,-21,+mar1, +mar2[CP5]/46,XY[15]	M3	1.83	54	I.	YES	Q	ATRA, ATRA + ATO ATRA + ATO + idarubicin decitabine + AA	4 -	CR CRm at 4 mo, but molecular relapse at 5 mo CRm	ATRA ATO, idarubicin, decitabine + CAG	8 mo; Ongoing

Wang et al. Medicine (2020) 99:43

Table 1

Medicine

and ATO at the beginning and achieved CRm after the fourth course; however, he relapsed quickly (molecular biology relapse). To date, a total of 16 cases of APL with STAT5B/RARa have been reported worldwide; this disease is extremely rare (Table 1). Only 3 patients were female, and more samples are needed to explain the sex-bias phenomenon. The age at onset was generally young; only 2 patients were over 60 years old. STAT5B/RARa is often accompanied by complex karyotypes (13 cases) and a high frequency of DIC (16 cases). ATRA can improve coagulation function in some patients (case 3, 9, 17), but granulocyte differentiation was observed in only 1 patient (case 15). Extramedullary infiltration in APL with PML/RARa is a rare event; even in patients without CR, 2 cases reported developed into extramedullary infiltration after CR (case 4 was CNS relapse, case 8 was testis relapse) (Table 1). Most patients received ATRA (monotherapy (n=9) or combined with ATO/ chemotherapy (n=7) in the first course of treatment (Table 1), but only 1 (ATRA monotherapy) and 3 patients (ATRA combined with ATO/chemotherapy) achieved CR after the first course. The CR rate is obviously lower in APL patients with STAT5B/RARa than in those with PML/RARa. After treatment with DA, IA (idarubicin and cytarabine), FLAG (fludarabine, cytarabine, and G-CSF), CAG (cytarabine, aclamycin, G-CSF), medium dose Ara-C, and DCAG, 12 patients achieved once CR at least in the whole course of treatment, 5 patients relapsed (case 2, 4, 8, 10, and 17), 5 patients died (case 2, 4, 5, 8, and 14) (Table 1). The CR rate and total mortality rate were 35.3% (6/17) and 47.1% (8/17) in APL with STAT5B-RARa, in contrast to 95% and 5% in APL with PML-RARa, respectively (Table 1). The main reasons of death were infections, progressive disease, cerebral hemorrhage or transplantation-related complications. Notably, 6 patients remained relapse-free until the report, 3 of them received combined chemotherapy (case 3, 13, 17), and another 3 received HSCT (case 6, 12, and 16). Among the 17 patients in Table 1, 7 patients received HSCT, and 4 patients died (the longest OS was 53 months). Patients failed to get CR when HSCT after relapse (case 2, 8), the best time for HSCT is after CR1. Until now, the standard treatment for variants APL was still unclear due to the small sample size. Therefore, it is critical to improve the prognosis of patients with new treatment methods. It should be noted that 2 patients (case 13, 17) got CR with decitabine + AA/IA or DCAG after relapse, and the role of decitabine in APL with STAT5B-RARa needs to be considered.

We can conclude that APL patients with STAT5B-RARa is not only resistant to ATRA, but also to conventional combination chemotherapy such as DA/IA or other regimens. Relapse and extramedullary infiltration is common, HSCT is a effective treatment, and the best time for HSCT is after the first CR.

Acknowledgments

The authors would like to thank American Journal Experts who provided language editing.

Author contributions

Data curation: Lei Wang. Funding acquisition: Xiaojing Yan. Software: Lei Wang.

Writing – original draft: Lei Wang.

Writing - review & editing: Lei Wang, Juan He.

References

- Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to alltrans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Int J Hematol 2013;97:717–25.
- [2] Adams J, Nassiri M. Acute promyelocytic leukemia: a review and discussion of variant translocations. Arch Pathol Lab Med 2015;139:1308–13.
- [3] Arnould C, Philippe C, Bourdon V, et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 1999;8:1741–9.
- [4] Strehl S, Konig M, Boztug H, et al. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. Leukemia 2013;27:1606–10.
- [5] Kusakabe M, Suzukawa K, Nanmoku T, et al. Detection of the STAT5B-RARA fusion transcript in acute promyelocytic leukemia with the normal chromosome 17 on G-banding. Eur J Haematol 2008;80:444–7.
- [6] Iwanaga E, Nakamura M, Nanri T, et al. Acute promyelocytic leukemia harboring a STAT5B-RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B-RARA. Eur J Haematol 2009;83:499–501.
- [7] Jovanovic JV, Rennie K, Culligan D, et al. Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia. Front Oncol 2011;1:35.
- [8] Qiao C, Zhang SJ, Chen LJ, et al. Identification of the STAT5B-RARalpha fusion transcript in an acute promyelocytic leukemia patient without FLT3, NPM1, c-Kit and C/EBPalpha mutation. Eur J Haematol 2011;86:442–6.
- [9] Chen H, Pan J, Yao L, et al. Acute promyelocytic leukemia with a STAT5b-RARalpha fusion transcript defined by array-CGH, FISH, and RT-PCR. Cancer Genet 2012;205:327–31.
- [10] Strehl S, König M, Boztug H, et al. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. Leukemia 2013;27:1606–10.
- [11] Wang YY, Hao J, Liu ZY, et al. Novel STAT5B–RARA fusion transcript in acute promyelocytic leukemia: identification and treatment response. Leuk Lymphoma 2015;56:2731–4.
- [12] Lirong L, Suning C, Junfeng T, et al. Acute promyelocytic leukemia with stat5b-RAR(fusion gene: a case report and literatures review. Zhonghua Xue Ye Xue Za Zhi 2016;37:68–70.
- [13] Zhang C, Wang Y, Liu B, et al. Clinical characteristics of acute promyelocytic leukemiawith the STAT5B-RARA fusion gene. Blood Cells Mol Dis 2018;69:71–3.
- [14] Kluk MJ, Abo RP, Brown RD, et al. Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom nextgeneration sequencing assay. Cold Spring Harb Mol Case Stud 2015;1: a000307.
- [15] Wang A, Cai X, Qiang P, et al. Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B/RARA fusion gene using decitabine. Leuk Lymphoma 2018;59:763–5.
- [16] Ciangola G, Gurnari C, Paterno G, et al. STAT5b-RARa-positive acute myeloid leukemia: diagnostic and therapeutic challenges of a rare AML subtype. Leuk Res 2019;78:21–3.
- [17] Peterson JF, He RR, Nayer H, et al. Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. Cancer Genet 2019;237:51–4.
- [18] Pessina C, Basilico C, Genoni A, et al. A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion. Leuk Lymphoma 2017;58:1977–80.